Ticker
AKTX

Price
1.16
Stock movement up
+0.02 (1.75%)
Company name
Akari Therapeutics PLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
68.85M
Ent value
57.65M
Price/Sales
-
Price/Book
4.94
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-30.95%
3 year return
-12.13%
5 year return
-21.93%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AKTX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book4.94
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count59.35M
EPS (TTM)-0.00
FCF per share (TTM)-0.00

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-16.91M
Net income (TTM)-16.76M
EPS (TTM)-0.00
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash16.72M
Net receivables0.00
Total current assets19.43M
Goodwill0.00
Intangible assets21.34K
Property, plant and equipment0.00
Total assets19.45M
Accounts payable3.08M
Short/Current long term debt0.00
Total current liabilities5.52M
Total liabilities5.52M
Shareholder's equity13.93M
Net tangible assets13.91M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-16.48M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-11.47M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-120.32%
Return on Assets-86.16%
Return on Invested Capital-120.32%
Cash Return on Invested Capital-82.36%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.14
Daily high1.17
Daily low1.13
Daily Volume18K
All-time high250.00
1y analyst estimate5.00
Beta1.27
EPS (TTM)-0.00
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
AKTXS&P500
Current price drop from All-time high-99.54%-12.18%
Highest price drop-99.67%-56.47%
Date of highest drop14 Jul 20229 Mar 2009
Avg drop from high-95.04%-11.38%
Avg time to new high2113 days12 days
Max time to new high2112 days1805 days
COMPANY DETAILS
AKTX (Akari Therapeutics PLC) company logo
Marketcap
68.85M
Marketcap category
Small-cap
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Employees
9
Investor relations
-
SEC filings
CEO
Clive Stuart Richardson
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports Akari’s focused pipeline inclu...
September 27, 2022
NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory disease...
September 22, 2022
NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory disease...
September 12, 2022
From what we can see, insiders were net buyers in Akari Therapeutics, Plc's ( NASDAQ:AKTX ) during the past 12 months...
September 8, 2022
NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases...
August 1, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
July 29, 2022
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related ...
July 28, 2022
Four patients have been enrolled in the Phase 3 Part A clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant related (HSCT) thrombotic microangiopathy (TMA); the Part A st...
July 20, 2022
NEW YORK and LONDON, July 07, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammato...
July 7, 2022
NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammato...
June 13, 2022
Next page